VolitionRx Limited Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VolitionRx Limited (NYSE American: VNRX) on May 15, 2026, covering events occurring on May 12, 2026. The filing addresses corporate governance changes regarding the Board of Directors ahead of the 2026 Annual Meeting of Stockholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and does not contain financial performance data.
Material Changes
- Director Departure: Mickie Henshall notified the Board on May 12, 2026, of her decision not to stand for re-election at the 2026 Annual Meeting.
- Board Composition: The Board size will be reduced from eight to seven directors, effective immediately prior to the 2026 Annual Meeting.
- Reason for Departure: Ms. Henshall's decision did not involve any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary on future performance. No specific risks, contingencies, or unusual items were disclosed in this report.
Key Facts for Investor Verification
- Confirm the exact date of the 2026 Annual Meeting of Stockholders to verify the timing of the Board size reduction.
- Verify if a replacement director has been nominated to fill the vacancy left by Ms. Henshall.
- Review the Company's proxy statement for the 2026 Annual Meeting for details on the remaining director slate.